Small-molecule inhibitors of dimeric transcription factors: Antagonism of protein–protein and protein–DNA interactions

No abstract is available for this paper.

• Publication year

  2012

• Venue

  MedChemComm

• Publication date

  2012-05-02

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1039/C2MD00289B
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Potent and selective phosphopeptide mimetic prodrugs targeted to the Src homology 2 (SH2) domain of signal transducer and activator of transcription 3.

  2011cited by this paper
• Artificially induced protein-membrane anchorage with cholesterol-based recognition agents as a new therapeutic concept.

  2011cited by this paper
• Design, synthesis, and in vitro characterization of novel hybrid peptidomimetic inhibitors of STAT3 protein.

  2011cited by this paper
• Antagonism of the Stat3–Stat3 Protein Dimer with Salicylic Acid Based Small Molecules

  2011cited by this paper
• Small‐Molecule Inhibitors of the ERK Signaling Pathway: Towards Novel Anticancer Therapeutics

  2011cited by this paper
• Identification of Purine-Scaffold Small-Molecule Inhibitors of Stat3 Activation by QSAR Studies

  2010cited by this paper
• Structure-Based Design of Conformationally Constrained, Cell-Permeable STAT3 Inhibitors.

  2010cited by this paper
• Coordination complex SH2 domain proteomimetics: an alternative approach to disrupting oncogenic protein-protein interactions.

  2010cited by this paper
• Boron-containing phenoxyacetanilide derivatives as hypoxia-inducible factor (HIF)-1alpha inhibitors.

  2010cited by this paper
• Concise access to N9-mono-, N2-mono- and N2,N9-di-substituted guanines via efficient Mitsunobu reactions

  2010cited by this paper
• Small‐Molecule Inhibitors of the Hedgehog Signaling Pathway as Cancer Therapeutics

  2010cited by this paper
• Identification of HSP60 as a primary target of o-carboranylphenoxyacetanilide, an HIF-1alpha inhibitor.

  2010cited by this paper
• Synthesis of phosphatase-stable, cell-permeable peptidomimetic prodrugs that target the SH2 domain of Stat3.

  2009cited by this paper
• Conformationally constrained peptidomimetic inhibitors of signal transducer and activator of transcription. 3: Evaluation and molecular modeling.

  2009cited by this paper
• Small molecule inhibitors of Myc/Max dimerization and Myc-induced cell transformation.

  2009cited by this paper
• Multiple independent binding sites for small-molecule inhibitors on the oncoprotein c-Myc.

  2009cited by this paper
• Nucleophilic addition of organozinc reagents to 2-sulfonyl cyclic ethers: stereoselective synthesis of manassantins A and B.

  2009cited by this paper
• Facile and efficient access to 2,6,9-tri-substituted purines through sequential N9, N2 Mitsunobu reactions

  2009cited by this paper
• Analysis of HIF-1 inhibition by manassantin A and analogues with modified tetrahydrofuran configurations.

  2009cited by this paper
• Discovery of inhibitors of aberrant gene transcription from Libraries of DNA binding molecules: inhibition of LEF-1-mediated gene transcription and oncogenic transformation.

  2009cited by this paper
• Structure-affinity relationships of glutamine mimics incorporated into phosphopeptides targeted to the SH2 domain of signal transducer and activator of transcription 3.

  2009cited by this paper
• Disruption of Transcriptionally Active Stat3 Dimers with Non‐phosphorylated, Salicylic Acid‐Based Small Molecules: Potent in vitro and Tumor Cell Activities

  2009cited by this paper
• Allosteric modulation of DNA by small molecules

  2009cited by this paper
• Inhibition of transcription factors with small organic molecules.

  2008cited by this paper
• Treatment of arthritis with a selective inhibitor of c-Fos/activator protein-1

  2008cited by this paper
• Disruption of the MYC transcriptional function by a small-molecule antagonist of MYC/MAX dimerization.

  2008cited by this paper
• Molecular Approaches towards the Inhibition of the Signal Transducer and Activator of Transcription 3 (Stat3) Protein

  2008cited by this paper
• Hypoxia-Inducible Factor 1 (HIF-1) Pathway

  2007cited by this paper
• Selective Inhibition of c‐Myc/Max Dimerization by a Pyrazolo[1,5‐a]pyrimidine

  2007cited by this paper
• Design and synthesis of a new, conformationally constrained, macrocyclic small-molecule inhibitor of STAT3 via 'click chemistry'.

  2007cited by this paper
• Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity

  2007cited by this paper
• Selective inhibition of c-Myc/Max dimerization and DNA binding by small molecules.

  2006cited by this paper
• Small molecule modulators of transcription.

  2006cited by this paper
• The Myc oncoprotein as a therapeutic target for human cancer.

  2006cited by this paper
• Programmable oligomers for minor groove DNA recognition.

  2006cited by this paper
• Discovery of nonpeptidic small-molecule AP-1 inhibitors: lead hopping based on a three-dimensional pharmacophore model.

  2006cited by this paper
• A credit-card library approach for disrupting protein-protein interactions.

  2006cited by this paper
• Identification of small molecules that induce apoptosis in a Myc-dependent manner and inhibit Myc-driven transformation.

  2006cited by this paper
• Mechanism of transcriptional activation by the Myc oncoproteins.

  2006cited by this paper
• Crystal structure of the boronic acid-based proteasome inhibitor bortezomib in complex with the yeast 20S proteasome.

  2006cited by this paper
• Investigation of the binding determinants of phosphopeptides targeted to the SRC homology 2 domain of the signal transducer and activator of transcription 3. Development of a high-affinity peptide inhibitor.

  2005cited by this paper
• Protein surface recognition and proteomimetics: mimics of protein surface structure and function.

  2005cited by this paper
• Regulation of the Versican Promoter by the β-Catenin-T-cell Factor Complex in Vascular Smooth Muscle Cells*

  2005cited by this paper
• Cancer therapeutics: targeting the dark side of Myc.

  2005cited by this paper
• Chemical approaches to transcriptional regulation.

  2005cited by this paper
• Transcriptional regulation and transformation by Myc proteins

  2005cited by this paper
• Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity.

  2005cited by this paper
• AP-1 subunits: quarrel and harmony among siblings

  2004cited by this paper
• Inhibition of vascular endothelial growth factor with a sequence-specific hypoxia response element antagonist.

  2004cited by this paper
• Design, synthesis, and biological evaluation of new cyclic disulfide decapeptides that inhibit the binding of AP-1 to DNA.

  2004cited by this paper
• Molecular-targeted antitumor agents: the Saururus cernuus dineolignans manassantin B and 4-O-demethylmanassantin B are potent inhibitors of hypoxia-activated HIF-1.

  2004cited by this paper
• Low molecular weight inhibitors of Myc–Max interaction and function

  2003cited by this paper
• X-ray structures of Myc-Max and Mad-Max recognizing DNA. Molecular bases of regulation by proto-oncogenic transcription factors.

  2003cited by this paper
• HIF-1 as a target for drug development

  2003cited by this paper
• New and known symmetrical curcumin derivatives inhibit the formation of Fos-Jun-DNA complex.

  2002cited by this paper
• c-MYC: more than just a matter of life and death

  2002cited by this paper
• Small-molecule antagonists of Myc/Max dimerization inhibit Myc-induced transformation of chicken embryo fibroblasts

  2002cited by this paper
• AP-1 as a regulator of cell life and death

  2002cited by this paper
• A Conserved Family of Prolyl-4-Hydroxylases That Modify HIF

  2001cited by this paper
• Resveratrol inhibits phorbol ester and UV-induced activator protein 1 activation by interfering with mitogen-activated protein kinase pathways.

  2001cited by this paper
• Structure, function, and dynamics of the dimerization and DNA-binding domain of oncogenic transcription factor v-Myc.

  2001cited by this paper
• AP-1 – Introductory remarks

  2001cited by this paper
• Momordin I, a compound of ampelopsis radix, inhibits AP-1 activation induced by phorbol ester.

  2000cited by this paper
• MYC oncogenes and human neoplastic disease

  1999cited by this paper
• The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis

  1999cited by this paper
• Identification of the von Hippel-lindau tumor-suppressor protein as part of an active E3 ubiquitin ligase complex.

  1999cited by this paper
• Alteration of Jun proto‐oncogene status by plasmid transfection affects growth of human ovarian cancer cells

  1999cited by this paper
• Recognition of the four Watson–Crick base pairs in the DNA minor groove by synthetic ligands

  1998cited by this paper
• K1115 A, a new anthraquinone derivative that inhibits the binding of activator protein-1 (AP-1) to its recognition sites. I. Biological activities.

  1998cited by this paper
• Disruption of IRS-2 causes type 2 diabetes in mice

  1998cited by this paper
• Inhibition of fos-jun-DNA complex formation by dihydroguaiaretic acid and in vitro cytotoxic effects on cancer cells.

  1998cited by this paper
• Studies on the contribution of c-fos/AP-1 to arthritic joint destruction.

  1997cited by this paper
• Constitutive Transcriptional Activation by a β-Catenin-Tcf Complex in APC−/− Colon Carcinoma

  1997cited by this paper
• Crystal structure of the heterodimeric bZIP transcription factor c-Fos–c-Jun bound to DNA

  1995cited by this paper
• Curcumin inhibits TPA induced expression of c-fos, c-jun and c-myc proto-oncogenes messenger RNAs in mouse skin.

  1994cited by this paper
• LEF‐1 contains an activation domain that stimulates transcription only in a specific context of factor‐binding sites.

  1993cited by this paper
• Transcription factors: structural families and principles of DNA recognition.

  1992cited by this paper
• Oncogenic and transcriptional cooperation with Ha-Ras requires phosphorylation of c-Jun on serines 63 and 73

  1991cited by this paper
• The role of Jun, Fos and the AP-1 complex in cell-proliferation and transformation.

  1991cited by this paper
• Suppression of c-Jun/AP-1 activation by an inhibitor of tumor promotion in mouse fibroblast cells.

  1991cited by this paper
• Phorbol ester-inducible genes contain a common cis element recognized by a TPA-modulated trans-acting factor.

  1987cited by this paper
• Protein-DNA recognition.

  1984cited by this paper
• Translocation of the c-myc gene into the immunoglobulin heavy chain locus in human Burkitt lymphoma and murine plasmacytoma cells.

  1982cited by this paper

• New insights into protein–protein interaction modulators in drug discovery and therapeutic advance

  2024cites this paper
• Transcription Factors and Cancer

  2023cites this paper
• Phenolic-protein interactions in foods and post ingestion: Switches empowering health outcomes

  2021cites this paper
• Design and synthesis of 14 and 15-membered macrocyclic scaffolds exhibiting inhibitory activities of hypoxia-inducible factor 1α.

  2020cites this paper
• Modulation of nuclear receptor function: Targeting the protein-DNA interface.

  2019cites this paper
• Integrating Experimental and In Silico HTS in the Discovery of Inhibitors of Protein-Nucleic Acid Interactions.

  2018cites this paper
• Medicinal chemistry in drug discovery in big pharma: past, present and future.

  2017cites this paper
• Downsizing Proto-oncogene cFos to Short Helix-Constrained Peptides That Bind Jun.

  2017cites this paper
• An effective layered workflow of virtual screening for identification of active ligands of challenging protein targets

  2017cites this paper
• The use of calorimetry in the biophysical characterization of small molecule alkaloids binding to RNA structures.

  2016cites this paper
• Small-molecule inhibitors identify the RAD52-ssDNA interaction as critical for recovery from replication stress and for survival of BRCA2 deficient cells

  2016cites this paper
• A rapid method for detecting protein-nucleic acid interactions by protein induced fluorescence enhancement

  2016cites this paper
• Combining library screening approaches, and modifying peptides with helix constraints, to generate novel antagonists of oncogenic Activator Protein-1

  2016cites this paper
• Polyphenol Compound as a Transcription Factor Inhibitor

  2015influential citation
• BRD4 Structure-Activity Relationships of Dual PLK1 Kinase/BRD4 Bromodomain Inhibitor BI-2536.

  2015cites this paper
• Inhibition of c-MYC with involvement of ERK/JNK/MAPK and AKT pathways as a novel mechanism for shikonin and its derivatives in killing leukemia cells

  2015cites this paper
• Small-molecule inhibitors of the Myc oncoprotein.

  2015cites this paper
• Perturbation of the c-Myc-Max protein-protein interaction via synthetic α-helix mimetics.

  2015cites this paper
• Small Molecules Targeting c-Myc Oncogene: Promising Anti-Cancer Therapeutics

  2014cites this paper
• Discovery of Methyl 4′‐Methyl‐5‐(7‐nitrobenzo[c][1,2,5]oxadiazol‐4‐yl)‐[1,1′‐biphenyl]‐3‐carboxylate, an Improved Small‐Molecule Inhibitor of c‐Myc–Max Dimerization

  2014cites this paper
• Glutaminase regulation in cancer cells: a druggable chain of events.

  2014cites this paper
• In silico studies of nucleic acid complexes with proteins, and therapeutic small molecules

  2013cites this paper
• Development of new N-arylbenzamides as STAT3 dimerization inhibitors

  2013cites this paper
• Protein–protein interactions: an emerging class of molecular targets for anticancer drugs

  2013cites this paper
• Pharmacophore identification of c-Myc inhibitor 10074-G5.

  2013cites this paper
• Disruption of Myc-Max Heterodimerization with Improved Cell-Penetrating Analogs of the Small Molecule 10074-G5

  2013cites this paper
• Fine-tuning the chemo- and regioselective alkylation of 1,4-benzodiazepines: further applications of the Mitsunobu reaction

  2012cites this paper
• ABCC4/MRP4: a MYCN-regulated transporter and potential therapeutic target in neuroblastoma

  2012cites this paper
• In Silico Inhibition Studies of Jun-Fos-DNA Complex Formation by Curcumin Derivatives

  2012cites this paper
• Targeted inactivation of transcription factors by overexpression of their truncated forms in plants.

  2012cites this paper